RANGAP1 and leukemia: Interestingly, RanGAP1 was frequently expressed in tumors with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93.3% [Figure 2C], and Burkitt lymphoma: 94.6% [Figure 2D]) or with cell-cycle aberrations (mantle cell lymphoma: 83.3% [Figure 2E], and Hodgkin’s lymphoma: 90.5% [Figure 2F]).